Diplomat Pharmacy, Inc. (NYSE: DPLO) investors took it on the chin in August after the company’s management reported second quarter sales that were below forecasts. However, investors might want to focus less on the second quarter miss and more on the company’s potential to win a greater share of the important and growing specialty pharmacy market.